Description
WinSanTor is a clinical-stage biotechnology company dedicated to discovering and developing treatments for peripheral neuropathies, such as diabetic neuropathy, chemotherapy-induced neuropathy, and HIV-related neuropathy.
The company is conducting Phase 3 clinical trials for its lead drug aimed at preventing and reversing nerve damage associated with these conditions. With a team of key opinion leaders and world-class advisors, WinSanTor is committed to enhancing patient lives through innovative therapies.
[View Datanyze profile here]
[View WinSanTor's website here]
About the Presenter
Stanley Kim is the CEO and Co-Founder of WinSanTor. He is a seasoned entrepreneur with a background in founding companies across various industries, including pharmaceuticals, biotechnology, medical devices, and software. His first company, SoftMax, was acquired by Qualcomm, and his second company, Emotient, was acquired by Apple. Both technologies now reside on most smartphones.
Stanley graduated from the University of California, Berkeley, where he studied genetics. After realizing he had no desire to work in a lab or attend medical school, he persued a career in law, becoming an intellectual property attorney. He eventually served as the Director of Intellectual Property at the Salk Institute for Biological Studies, a leading biology institution.
Thursday, April 24th
1pm Pacific / 2pm Mountain / 3pm Central / 4pm Eastern